Tenofovir Emtricitabine Efavirenz

Fact of Medicine

  • Medicine Name: Viraday/Teevir
  • API: Efavirenz/Emtricitabine/Tenofovir
  • Packaging: Oral Tablets
  • Strength: 600mg/200mg/300mg
Get Price


Uses of medication:

Efavirenz Emtricitabine Tenofovir, a fixed-dose combination of 2 nucleoside analog HIV-1 reverse transcriptase inhibitors and 1 non-nucleoside HIV-1 reverse transcriptase inhibitor, is used alone as a complete regimen or together with other antiretroviral agents for the treatment of HIV-1 infection in adults and pediatric patients aged 12 years and older. 


Efavirenz Emtricitabine Tenofovir is available as tablets. Each tablet contains 600 mg of efavirenz, 200 mg of emtricitabine and 300 mg of tenofovir DF (tenofovir DF, which is equivalent to 245 mg of tenofovir disoproxil). 

The recommended dose in adults and pediatric patients (aged 12 years and older and weighing at least 40 kg) is one tablet once daily taken orally on an empty stomach, preferably at bedtime. Dosing at bedtime may help boost the tolerability of nervous system signs/symptoms.

Because Efavirenz/Emtricitabine/Tenofovir is a fixed-dose combination, it should not be used for patients requiring dosage adjustment such as those with moderate/severe renal impairment (estimated creatinine clearance below 50 mL/min).

When Efavirenz 600 mg Emtricitabine 200 mg Tenofovir 300 mg is administered with rifampin, an additional 200 mg/day of efavirenz is recommended for patients weighing 50 kg or more.

Treatment Reactions:

The most commonly reported side effects due to efavirenz, emtricitabine, and tenofovir DF may include:

  • rash
  • diarrhea
  • nausea
  • fatigue
  • headache
  • dizziness
  • depression
  • insomnia
  • abnormal dreams

Warnings and Precautions:

  • Precise caution is needed when using nucleoside analogs in any patient with known risk factors for liver disease; however, cases have also been seen in patients with no known risk factors.
  • Suspend treatment with Efavirenz 600 mg Emtricitabine 200 mg Tenofovir 300 mg in any patient who develops clinical/laboratory findings suggestive of lactic acidosis or pronounced hepatotoxicity (which may include steatosis and hepatomegaly even in the non-existence of marked transaminase elevations).
  • It is recommended that all patients with HIV-1 be tested for the existence of chronic HBV prior to initiating ART. The efavirenz emtricitabine and tenofovir is not for chronic HBV infection, and the safety and efficacy have not been established in patients coinfected with HBV and HIV-1.
  • Patients, coinfected with HIV-1 and HBV should be precisely monitored with clinical as well as laboratory follow-up for at least some months after halting therapy with Efavirenz Emtricitabine Tenofovir. If apt, initiation of anti-hepatitis B therapy may be warranted. This medicine should not be administered with adefovir dipivoxil.
  • Convulsions may occur in adult and pediatric patients taking efavirenz, typically in the presence of previous medical history of seizures. Caution needs to be taken in any patient with a history of seizures. Patients who are with concomitant anticonvulsant medicines primarily metabolized by the liver, such as phenobarbital and phenytoin, may require periodic assessment of plasma levels.
  • Monitoring of liver enzymes prior to and during therapy is needed for patients with underlying hepatic disease, including hepatitis B/C infection; patients with marked transaminase elevations; and patients treated with other drugs associated with liver toxicity.
  • Emtricitabine Tenofovir are principally eliminated by the kidney; however, efavirenz is not. Since this combination product and the dose of the individual components cannot be altered, patients with estimated creatinine clearance of less than 50 mL/min should not receive treatment.
  • Patients receiving this medicine should be alerted to the potential for additive central nervous system effects when it is used concomitantly with alcohol or psychoactive drugs. Patients who experience central nervous system symptoms should avoid potentially hazardous activities such as driving or operating machinery.
  • Related medicines not for coadministration with efavirenz emtricitabine tenofovir include emtricitabine rilpivirine tenofovir DF, emtricitabine, elvitegravir/cobicistat/emtricitabine/tenofovir DF, emtricitabine/tenofovir DF, and tenofovir DF, which contain the same active components as efavirenz emtricitabine tenofovir.
  • This FDC medicine should not be coadministered with drugs containing lamivudine, including lamivudine/zidovudine, abacavir sulfate/lamivudine, or abacavir sulfate/lamivudine/zidovudine.
  • Efavirenz may cause fetal harm if administered during the 1’st trimester to a pregnant woman. Avoid pregnancy in women with Efavirenz Emtricitabine Tenofovir. Barrier contraception should always be considered along with other methods of contraception (e.g., oral or other hormonal contraceptives).

More Info.


Store at 25°C (77°F); excursions permitted to 15°C to 30°C (59°F to 86°F). Keep the container tightly closed. Dispense only in the original container. Do not use it if the seal over the bottle opening is broken or missing.

Availability in India:

The Indian Pharma helps connect buyers with suppliers who can ship Efavirenz/Emtricitabine/Tenofovir at the global level as per the needs of buyer’s. The Indian Pharma provides a guarantee of quality and delivery for the Efavirenz/Emtricitabine/Tenofovir Tablets.

Buying Procedure:

In order to buy Efavirenz Emtricitabine Tenofovir, you can contact us at our Toll-free Number 1800 889 1064 or on WhatsApp number +91 8130290915 or an Email to us at:info@theindianpharma.com along with your Proof of Identity, Valid Prescription and Medical Reports. 


Efavirenz Emtricitabine Tenofovir is a potent and effective single pill once-daily antiretroviral regimen. However, further drug development and coformulations of other antiretroviral (ART) drugs, particularly with a once-daily administration, are required because some patients cannot tolerate or are resistant to Efavirenz & Emtricitabine & Tenofovir. Given also that this FDC medicinal product cannot be utilized during pregnancy or breastfeeding, alternative coformulations need to be developed. In addition, monitoring for long-term effects is still needed for Efavirenz/Emtricitabine/Tenofovir, consideration for its use in resource-limited settings. As always, further investigation is needed.

Commonly Asked Questions

What is Efavirenz Emtricitabine Tenofovir ?

Efavirenz Emtricitabine Tenofovir (600mg/200mg/300mg) is a well-known, well-described antiviral combination medication for the treatment of HIV.

Is Efavirenz/emtricitabine/tenofovir available as generic medicine? 

Yes, It is available as a generic medicine.

Are Viraday and Teevir medicines the same for HIV?

Yes, Both are the same, having the combination of three medicines (Efavirenz emtricitabine tenofovir) in one.

How much does Efavirenz Emtricitabine Tenofovir or Teevir cost?

Efavirenz Emtricitabine Tenofovir or Teevir cost in India can vary. In order to procure it authentically, you can get in touch with us either via TOLL-FREE Number: 1800 889 1064 or WhatsApp: +918130290915 or Email:info@theindianpharma.com.

Where can I get Efavirenz/Emtricitabine/Tenofovir at the best price?

In order to get the best efavirenz emtricitabine and tenofovir price in India, always buy this medication from a Pharmaceutical Wholesaler Company which is certified by the higher authorities like WHO-GDP & ISO 9001:2008.

Can I get Efavirenz/Emtricitabine/Tenofovir even if I am not based in India?

The Indian Pharma helps patients in accessing or importing Efavirenz/Emtricitabine/Tenofovir, not approved in their home country against the legitimate prescription and in conformity with the all local laws and regulations of their home country.

Is it safe to buy Efavirenz/Emtricitabine/Tenofovir online in India? 

Yes, You can buy efavirenz emtricitabine and tenofovir online in India authentically from https://theindianpharma.com/ if the product has not been approved or is not available in your home country.